What’s new in nano
Every dated step in the nanotechnology we track, newest first. Each one says what happened, why it matters and how far it is from your life, with its source. New ones arrive every morning.
1 step
Oct 2026
- mRNA cancer vaccine
Full results from 1,137 patients, presented at the ESMO Congress in Madrid: adding the vaccine to Keytruda cut the risk of recurrence or death by 42%.
Real-world testing
1 step
Sept 2026
- NBTXR3
Nanobiotix reported that the FDA had cleared changes to the Johnson & Johnson-led phase 3 trial in head and neck cancer, NANORAY-312, so that its final analysis can come sooner.
Approved or on sale
1 step
Aug 2026
- mRNA cancer vaccine
Merck and Moderna said their phase 3 trial in people whose high-risk melanoma had been removed met its main goal: with Keytruda, the vaccine lowered the risk of the cancer returning.
Real-world testing
1 step
Jan 2026
- In-body gene editing
The FDA lifted the hold on MAGNITUDE-2, the trial in the nerve form of the disease, with closer monitoring of liver tests. The hold on the heart trial, MAGNITUDE, stayed.
Real-world testing
1 step
Nov 2025
- Microrobots
ETH Zurich researchers reported in Science that they steered drug-carrying microrobots through the blood vessels of pigs and the brain fluid of a sheep; in more than 95% of tests the drug reached the right spot. Their next goal is trials in people.
Working prototype
1 step
Oct 2025
- In-body gene editing
The FDA put Intellia's two phase 3 trials of nex-z on hold after a patient had severe liver injury. The patient died on November 5, 2025.
Real-world testing